In 1996, Dr. Keith R. Latham founded ITL Pharma, a drug discovery company, and set out to take on major diseases and ailments. Dr. Latham and his team began developing new, better treatments and diagnostics in the areas of Parkinson's Disease, Thyroid Replacement, Cancer Diagnostics, Cancer Therapy, Alzheimer's Disease, Heart Attack Recovery, Attention Deficit/Hyperactivity Disorder, Anti-Inflammatory, Wound-Healing and Tissue Repair, Cell Culture and others; most of which deal with oxidative free-radicals, which are highly reactive chemicals that cause physiologic damage if they are released into the body. Today, ITL has an R&D Pipeline with 38 candidates, addressing nine therapeutic areas. One of these candidates is entering Phase I clinical trials and several are ready for regulatory review. As ITL continues to grow in a global market, our company is searching for strategic partners to further develop our R&D Pipeline and increase sales of current products and chemicals.